Liquidia Corporation (NASDAQ:LQDA) Q3 2023 Earnings Call Transcript
Liquidia Corporation (NASDAQ:LQDA) Q3 2023 Earnings Call Transcript November 7, 2023
Liquidia Corporation misses on earnings expectations. Reported EPS is $-0.24 EPS, expectations were $-0.2.
Operator: Good morning, and welcome everyone to the Liquidia Corporation Third Quarter 2023 Financial Results and Corporate Update Conference Call. My name is Therese [ph], and I will be your conference operator today. Currently, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up for questions. I would like to remind everyone that this conference call is being recorded. I will now hand the conference call over to Jason Adair, Chief Business Officer.
Jason Adair: Thank you, Therese. It's my pleasure to welcome everyone to Liquidia's third quarter 2023 financial results and corporate update conference call. Joining the call today are, Chief Executive Officer, Dr. Roger Jeffs; Chief Financial Officer, Michael Kaseta; Chief Commercial Officer, Scott Moomaw, Chief Medical Officer, Dr. Rajeev Saggar and General Counsel, Rusty Schundler. Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results or performance to be materially different from any future results or performance expressed or implied on this call.
For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. I would now like to turn the call over to Roger for our prepared remarks, after which, he will open-up the call up for your questions.
Roger Jeffs: Thank you, Jason. Good morning, everyone and thank you for joining us. The third quarter was marked by continued and positive steps to change the future of the company, the PH market and the lives of patients we are committed to serve. We have built a portfolio that we believe includes the most promising products in the fastest-growing area of the PH marketplace in treprostinil for the treatment of pulmonary arterial hypertension or PAH; and pulmonary hypertension associated with interstitial lung disease or PH-ILD. Many of you know already that YUTREPIA, our dry powder formulation of treprostinil using a low effort, simple-to-use pocket-sized dry powder inhaler has the potential to be the first and best choice when adding the prostacyclins to a patient's treatment regimen.
In support of this, a recent summary from our open-label clinical experience shows how durable and titratable YUTREPIA treatment can be, where we've treated patients for as long as 5.5 years and have titrated to doses now equivalent to 30 breaths of Tyvaso four times per day. I want to emphasize those matters, as it has been demonstrated across all routes of prostacyclin use that higher doses equate with better patient outcomes. YUTREPIA's ability to dose higher has the potential to significantly broaden and improve upon the therapeutic index and utility of inhaled treprostinil administration as it currently exists. At the same time, we've seen promising early evidence of clear benefits in our sustained-release inhaled treprostinil program called L606.
See also 10 Best Engineering Stocks to Buy Now and 14 Best Broadcasting Stocks To Buy.
To continue reading the Q&A session, please click here.
